July 30, 2020
A new multi-institution, dose-determining clinical trial of a compound against metastatic, castration-resistant prostate cancer showed promising results, researchers reported in Clinical Cancer Research. The phase 1b/2a study of the pan-BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide was led by researchers at the University of Michigan Rogel Cancer Center, the University of California, San Francisco, […]